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Summary
Glycogen-storage diseases type I (GSD type I) are due
to a deficiency in glucose-6-phosphatase, an enzymatic
system present in the endoplasmic reticulum that plays
a crucial role in blood glucose homeostasis. Unlike GSD
type Ia, types Ib and Ic are not due to mutations in the
phosphohydrolase gene and are clinically characterized
by the presence of associated neutropenia and neutrophil
dysfunction. Biochemical evidence indicates the presence
of a defect in glucose-6-phosphate (GSD type Ib) or in-
organic phosphate (Pi) (GSD type Ic) transport in the
microsomes. We have recently cloned a cDNA encoding
a putative glucose-6-phosphate translocase. We have
now localized the corresponding gene on chromosome
11q23, the region where GSD types Ib and Ic have been
mapped. Using SSCP analysis and sequencing, we have
screened this gene, for mutations in genomic DNA, from
patients from 22 different families who have GSD types
Ib and Ic. Of 20 mutations found, 11 result in truncated
proteins that are probably nonfunctional. Most other
mutations result in substitutions of conserved or semi-
conserved residues. The two most common mutations
(Gly339Cys and 1211–1212 delCT) together constitute
∼40% of the disease alleles. The fact that the same mu-
tations are found in GSD types Ib and Ic could indicate
either that Pi and glucose-6-phosphate are transported
in microsomes by the same transporter or that the bi-
ochemical assays used to differentiate Pi and glucose-6-
phosphate transport defects are not reliable.
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Introduction
Glycogen-storage diseases type I (GSD type I [also
known as “von Gierke disease”) are recessive disorders
due to a deficiency in glucose-6-phosphatase (reviewed
in Chen and Burchell 1995), the enzymatic system that
catalyzes the terminal step of gluconeogenesis and gly-
cogenolysis in the endoplasmic reticulum (Hers et al.
1951). According to the substrate-transport model, this
system comprises a hydrolase, whose catalytic site faces
the lumen of the endoplasmic reticulum, as well as trans-
porters for glucose-6-phosphate, Pi (Arion et al. 1975,
1980), and glucose (Waddell et al. 1991). The glucose-
6-phosphate transporter is assumed to be specific for
glucose-6-phosphate (as opposed to its 2-epimer man-
nose 6-phosphate), to account for the specificity of the
enzyme in intact microsomes. The Pi transporter is ap-
parently also able to transport inorganic pyrophosphate
(PPi), at least at acidic pH, explaining the pyrophos-
phatase activity under these conditions (Arion et al.
1980). The glucose transporter had been identified as
Glut 7 (Waddell et at. 1992), which has, however, been
recently reported to be a cloning artifact (Burchell 1998).
Alternative models, known as “conformational mod-
els,” have been proposed, by other authors, both to ac-
count for the effect that detergents have on the kinetic
properties of glucose-6-phosphatase (Schulze et al. 1986;
Berteloot et al. 1991) and to explain the fact that glu-
cose-6-phosphate transport and its hydrolysis appear to
be tightly linked (St.-Denis et al. 1995).
The most frequent form of GSD type I, called “type
Ia” (MIM 232200), is caused by mutations in the gene,
present on chromosome 17, that encodes phosphohy-
drolase (Lei et al. 1993, 1995). This gene is not mutated
in some patients with a more severe form of the disease,
in which neutropenia and neutrophil dysfunction are
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found (reviewed by Gitzelmann and Bosshard 1993) in
addition to the clinical symptoms typical of GSD type I
(i.e., hepatomegaly, hypoglycemia, and hyperlacta-
temia). In these patients, there is evidence of defects in
either the glucose-6-phosphate translocase (type Ib;
MIM 232220; Narisawa et al. 1978; Lange et al. 1980)
or the Pi translocase (type Ic; MIM 232240; Nordlie et
al. 1983). In both cases, the glucose-6-phosphatase ac-
tivity is abnormally latent in intact microsomes. In type
Ic, there is also a complete latency of inorganic pyro-
phosphatase (Nordlie et al. 1983). However, the two
conditions are difficult to differentiate clinically (Chen
and Burchell 1995), since both show neutropenia in ad-
dition to the classical symptoms of GSD type I.
We have recently cloned a cDNA encoding a putative
glucose-6-phosphate translocase, which we found to be
mutated in two patients with GSD type Ib (Gerin et al.
1997). Independently, GSD types Ib (Annabi et al. 1998)
and Ic (Fenske et al. 1998) have been mapped to chro-
mosomes 11q23 and 11q23-24.2, respectively. We now
show that the gene encoding the putative translocase is
in this region and is mutated in 26 patients from a total
of 22 families, who have been diagnosed as GSD type
Ib or type Ic.
Patients and Methods
Patients and Diagnosis of GSD Types Ib and Ic
All patients had hepatomegaly, hypoglycemia, lactic
acidosis, and neutropenia. The diagnosis of GSD type
Ib was based on both the finding of normal or elevated
total glucose-6-phosphatase activity and the existence of
a significant latency (latency is defined as the enzymic
activity revealed by detergents, and it is often expressed
in terms of percent of the total activity) of this enzyme
(Narisawa et al. 1978; Lange et al. 1980). Assays were
performed on sucrose homogenates prepared either from
unfrozen liver biopsies or from liver samples that had
been frozen immediately after being collected (Brown
1985).
One case with apparently normal glucose-6-phospha-
tase latency (patient 18c; table 1) was diagnosed as GSD
type Ic, on the basis of complete latency of inorganic
pyrophosphatase in intact microsomes (Nordlie et al.
1983); the two other affected members of the family
were assumed to have the same form of disease; one of
them indeed showed a normal glucose-6-phosphatase
latency (Fenske et al. 1998). Patient 22 showed a sub-
normal glucose-6-phosphatase latency; the activity with-
out detergent amounted to 54% of the activity with
detergent; his condition was tentatively identified as
GSD type Ic.
Mapping of the Gene to Chromosome 11
A 671-bp human-specific fragment of the glucose-6-
phosphate translocase gene was amplified by a sense
primer (5′-GGA GAG CAC CCA CAG CTA AGG GGA-
3′) in exon 3 and by an antisense primer (5′-GGA CTC
CGC AAC CTG GAC CCC ATG-3-′) in exon 4. This
amplification reaction was used to screen the low-res-
olution GeneBridge 4 radiation-hybrid panel (Research
Genetics), by means of the following PCR program:
95C for 5 min; 35 cycles of 95C for 30 s, 70C for 30
s, and 72C for 1 min; and 72C for 5 min. Mapping
was computed by the RH Mapper program, available
on-line at the Whitehead Institute for Genome Research,
Massachusetts Institute of Technology.
SSCP Analysis and Sequencing
Genomic DNA was isolated from leukocytes by use
of the QIAmp Blood Kit (QIAGEN), according to the
manufacturer’s instructions. SSCP analysis (Orita et al.
1989) was used to screen all nine exons, as well as the
flanking intronic sequences. PCR reactions were per-
formed with primers in 10-ml volumes containing 10–20
ng of genomic DNA template, 1 # PCR buffer (Boeh-
ringer), 180 mM of each dNTP, 0.2 mM of each 32P–end-
labeled primers (table 2), and 0.5 U of Taq DNA poly-
merase (Boehringer). The PCR conditions were 95C for
5 min; 30 cycles of 95C for 30 s, 65C for 1 min, and
72C for 1 min; and 72C for 5 min. Amplified samples
were diluted 1:6.5 in formamide buffer (95% formam-
ide, 10 mM NaOH, 0.025% bromophenol blue, and
0.025% xylene cyanol), denatured at 95C for 5 min,
and rapidly cooled on ice. For each sample, 5 ml was
loaded onto a 0.5 # MDE, 0.6 # Tris-borate EDTA
gel (FMC Bioproducts). The gels were run at 6 W (con-
stant power) for 14–16 h at room temperature before
being dried and subjected to autoradiography. Direct
sequencing of PCR products showing a shift in SSCP
analysis was performed on both strands by the dsDNA
Cycle Sequencing System (GIBCO-BRL), according to
the manufacturer’s protocol. The PCR products were
purified, before being sequenced, by means of a QIA-
quick PCR Purification Kit (QIAGEN).
The Gly339Cys mutation was detected by allele-spe-
cific PCR (Gerin et al. 1997), under the following con-
ditions: 95C for 5 min; 35 cycles of 95C for 30 s, 57C
for 30 s, and 72C for 1 min; and 72C for 5 min. The
sequences of the primers were as follows: TGG TAT
TGG GAG CTG TAT TTG (5′ wild-type primer), TGG
TAT TGG GAG CTG TAT TTT (5′ mutated primer),
and GAG CGT GCA GGG GGA AGG CCA CCG (3′
common primer). The presence of this mutation was also
confirmed by sequencing of exon 8 in the manner de-
scribed above.
Table 1
Distribution of Mutations in Investigated Patients
PATIENT
(SEX)
MUTATIONa
ORIGIN/ETHNICITY CONSANGUINITY
DIAGNOSIS
(GSD TYPE)Allele 1 Allele 2
1 (M) Gly20rAspb Gly20rAspc United States/Caucasian No Ib
2 (M) Gly88rAsp Gly88rAsp Senegal/Black Yes Ib
3 (F) Gly68rArgb Gly339rCysc Italy and United Kingdom/Caucasian No Ib
4 (F) Gly339rCys Gly339rCys Belgium/Caucasian No Ib
5 (F) Gly339rCys Gly339rCys Belgium/Caucasian No Ib
6a (M) Gly339rCysb Gly339rCysc United States/Caucasian No Ib
6b (F) Gly339rCysb Gly339rCysc United States/Caucasian No Ib
7 (F) Gly339rCys Glu355rStop Belgium/Caucasian No Ib
8 (F) Gly339rCys DRF Ala347c United States/Caucasian No Ib
9 (F) Gln218rStopb Ser55rArgc United States/Caucasian No Ib
10 (F) Gln248rStop Gln248rStop Italy/Caucasian No Ib
11 (F) DRF Ala347 Gly292rPro; Leu293rStopc United States/Caucasian No Ib
12a (F) DRF Pro153 DRF Ala347c United Kingdom/Caucasian No Ib
12b (F) DRF Pro153 DRF Ala347c United Kingdom/Caucasian No Ib
13 (M) DRF Thr312b DRF Thr312c Pakistan/Caucasian Yes Ib
1393GrA (silent) 1393GrA (silent)
14 (M) DRF Pro345 DRF Ala347 Germany/Caucasian No Ib
15 (M) DRF Ala347b DRF Ala347c Portugal/Caucasian No Ib
16 (M) DRF Ala347b DRF Ala347c Tunisia/Caucasian No Ib
17 (F) DRF Ala347b Insertion of 4-amino-acid repeat after Met311c United States/Caucasian No Ib
18a (M) S Exon 8/intron 8b S Exon 8/intron 8c Pakistan/Caucasian Yes Ic
18b (F) S Exon 8/intron 8b S Exon 8/intron 8c Pakistan/Caucasian Yes Ic
18c (M) S Exon 8/intron 8b S Exon 8/intron 8c Pakistan/Caucasian Yes Ic
19 (M) S Exon 8/intron 8b S Exon 8/intron 8c Pakistan/Caucasian Yes Ib
20 (M) S Intron 8/exon 9 S Intron 8/exon 9 Sardinia/Caucasian No Ib
Asn198rIle (polymorphism?) Asn198rIle (polymorphism?)
1231CrT (silent) 1231CrT (silent)
1393GrA (silent) 1393GrA (silent)
21 (M) Arg28rCysb Gly150rArgc France/Caucasian No Ib
22 (F) Trp96rStop Insertion of 4-amino-acid repeat after Met311 United Kingdom/Caucasian No Ic
1393GrA (silent)
a When available, the DNA from the parents was analyzed by SSCP and/or allele-specific PCR, to identify parental origin of the mutation. DRF  change in reading frame, and
S  splice-site mutation.
b Paternal allele.
c Maternal allele.
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Table 2
Primers Used for SSCP Analysis
AMPLIFIED
REGION
PRIMERa
FRAGMENT
LENGTH
(bp)Forward Reverse
Exon 1 (5′) CAGTTTGGCGCTCAGTAATCTCb ATGGCTGAGAAGATCACAGTGCc 300
Exon 1 (3′) CAGGAACTGTGGTCAGAGGCTGTc TGTCTGGCTGGTTCTGTGTCC 259
Exon 2 TCCTGTGTTTCTCCCCTGGTC TTAGGCATCCTCTATGACAATCC 332
Exon 3 ATGGGCAGTAGGCTGGACACC TGCCTGCTAAATGAGTGCCCC 334
Exon 4 GGTTCAGGTTGGGGAGAGCAG TCCTGCTCCTTATGCCCACCC 262
Exon 5 CTTCCCTTCCCTCTTCCCACC CGTGAAGACTGAAAGGGACCC 175
Exon 6 GGTGTTCTCTGCCCTGTTCTG AGGGAGACAGAGTCAGTGGCC 238
Exon 7 CTCCTCCACTCTGGGCCTGG CAAAGGTGAGACAGACCAGGAG 162
Exon 8 TCCGACTCTGAATGCCACTCC TGCAAAGCACAGGTGGGGGTG 226
Exon 9 CCACTGGCTTAGGTTCTTCCC ACCGTGTGATGGTGCTCCGGc 236
a Primers are intronic, unless noted otherwise.
b In the promoter region.
c Exonic primer.
Figure 1 Representative SSCP patterns for mutations identified
in exons 2 and 8 (A) and in allele-specific PCR analysis of the
Gly339Cys mutation (B). In panel B, amplification products of ge-
nomic DNA from a control and from patients heterozygous (heteroz.)
or homozygous (homoz.) for the Gly339Cys mutations are shown. D
 change in reading frame, W.T.  wild type, and S  splice-site
mutation.
Results
Chromosomal Localization of the Glucose-6-Phosphate
Transporter
Using the GeneBridge 4 radiation-hybrid panel, we
mapped the gene encoding the putative glucose-6-phos-
phate translocase (Gerin et al. 1997), between markers
NIB 361 and WI-9009, to 11q23—that is, the region
linked to GSD types Ib and Ic (Annabi et al. 1998; Fenske
et al. 1998).
Mutation Detection in the Glucose-6-Phosphate
Transporter
To enable us to search for mutations at the genomic
level, we cloned the human glucose-6-phosphate trans-
locase gene from a genomic DNA library, using as a
probe the full-length cDNA (Gerin et al. 1997), and
determined its intron-exon structure. Nine exons were
identified, the first of which contained the initiating ATG
codon and the last of which contained the stop codon
and the 3′ UTR. Exon 7 is not present in liver cDNA
(Gerin et al. 1997), but it is in expressed sequence tags
derived from human brain libraries. It is 66 bp in length
and introduces 22 residues between amino acids Lys337
and Leu338 (I. Gerin, M. Veiga-da-Cunha, and E. Van
Schaftingen, unpublished data).
Intronic and, when necessary, exonic PCR primers
were used to amplify genomic DNA from patients di-
agnosed as GSD types Ib or type Ic. Exon 1 was am-
plified in two parts, because of its size, and only the
coding region of exon 9 was analyzed. The primers used
and the sizes of the expected fragments are shown in
table 2. As shown in figure 1A, SSCP analysis and se-
quencing allowed the identification of the mutations
listed in table 3, except for the Gly339Cys mutation;
this mutation, which had been previously identified in
980 Am. J. Hum. Genet. 63:976–983, 1998
Table 3
Mutations Identified in Patients with GSD Types Ib and Ic
Nucleotide Changea Location Effect on Proteinb
Amino Acid(s) at
Same Position in
Bacterial Transporters Patient(s)c
Substitutions:
228GrA Exon 1 Gly20rAsp Gly 1
271CrT Exon 1 Arg28rCys Arg 21
332ArC Exon 2 Ser55rArg Leu, Gly, Cys 9
371GrA Exon 2 Gly68rArg Gly, Ser 3
431GrA Exon 2 Gly88rAsp Gly, Ala 2
617GrA Exon 3 Gly150rArg Gly, Ala 21
762ArT Exon 3 Asn198rIle (polymorphism? [see text]) Ala, Pro, Ser, Lys 20
1184GrT Exon 8 Gly339rCys Gly 3–5, 6a, 6b, 7, 8
Nonsense mutations:
456GrA Exon 2 Trp96rStop 22
821CrT Exon 4 Gln218rStop 9
911CrT Exon 4 Gln248rStop 10
1232GrT Exon 8 Glu355rStop 7
Deletions/insertions:
629delA Exon 3 DRF after Pro153, Stop at 211 12a, 12b
1103ins12 (see fig. 2b) Exon 6 4-amino-acid repeat after Met311 17, 22
1105insA Exon 6 DRF after Thr312, Stop at 325 13
1205insC Exon 8 DRF after Pro345, Stop at 401 14
1211–1212 delCT Exon 8 DRF after Ala347, Stop at 400 8, 11, 12, 14–17
Splice site mutations:
1041ins9 (see fig. 2a) Intron 5/exon 6 Gly292rPro, Leu293rStop 11
Deletion of 4 bp (see fig. 2c) Exon 8/intron 8 Truncated protein? 18a, 18b, 18c, 19
Deletion of 2 bp (see fig. 2d) Intron 8/exon 9 Truncated protein? 20
a The position refers to the cDNA sequence (EMBL/Genbank accession number Y15409).
b Residues found in the same position in the sequences of bacterial organophosphate transporters (Gerin et al. 1997) are shown. DRF 
change in reading frame.
c Numbered as in table 1.
the cDNA from two patients, could be easily detected
by amplification with allele-specific primers (fig. 1B).
Eight substitutions were identified; six of them resulted
in replacement of a residue that is either partially (Gly68,
Gly88, and Gly150) or completely (Gly20, Arg28, and
Gly339) conserved in the bacterial organophosphate
transporters, which belong to the same protein family
that contains the human glucose-6-phosphate translo-
case (Gerin et al. 1997). We also identified four nonsense
mutations and four other nucleotide changes that re-
sulted in a frameshift that was due to either insertion of
1 bp or deletion of 1 or 2 bp. Two splice-site mutations
(exon 8/intron 8 and intron 8/exon 9), which are likely
to cause exon skipping (fig. 2c and d), were also found.
A 9-bp insertion at the intron 5/exon 6 boundary intro-
duces a premature stop codon (fig. 2b), and a 12-bp
insertion in exon 6 results in a 4-amino-acid insertion
(fig. 2a) in a predicted transmembrane domain.
Distribution of Mutations
The distribution of mutations among the patients is
shown in table 1. The two most frequent mutations are
Gly339Cys, which is found in the homozygous state in
patients from four unrelated families, and a 2-bp dele-
tion resulting in a change in reading frame after Ala347,
homozygous in two families. Most patients affected by
one of these two mutations originate from western Eu-
rope or the United States. Other mutations were found
in only one or two families. One patient was homozy-
gous for both a substitution (Asn198Ile), which could
be a polymorphism, and a splice-site mutation at the
intron 8/exon 9 junction (fig. 2d), as well as for two
silent nucleotide replacements. This multiple polymor-
phism could be related to the fact that this patient orig-
inates from Sardinia, which has a genetically isolated
population.
Presence of Mutations in the Same Gene in GSD
Type Ic
Interestingly, a splice-site mutation at the exon 8/in-
tron 8 junction was found to be homozygous in two
families of Pakistani origin, one diagnosed as GSD type
Ic and the other diagnosed as GSD type Ib; the first
family was used to map the GSD Ic locus to 11q23-
24.2 (Fenske et al. 1998). A patient from another family,
also diagnosed as GSD type Ic, was heterozygous for a
mutation found in a patient with GSD type Ib (a 4-
amino-acid insertion) and a missense mutation.
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Figure 2 Complex mutations found in the translocase gene (a–d), and localization of exons and mutations in the amino acid sequence
(e). In panels a–d, exonic sequences are represented as uppercase letters, intronic sequences as lowercase letters. In panels a and b, the repeated
elements found in the wild-type gene are underlined, and the arrows denote the sequence that is repeated in the mutated allele. In panels c and
d, the nucleotides that are missing in the mutated alleles are in boldface italics. In panel e, amino acid residues are represented in terms of the
one-letter code, and exon limits are denoted by arrows; the retention signal for the endoplasmic reticulum is underlined. Mutations are shown
below the sequence: letters indicate substitutions or insertions (X  stop codon), *  changes in reading frame, and S  splice-site mutation.
Discussion
Previous studies had indicated that GSD types Ib and
Ic map to the same region of chromosome 11 (Annabi
et al. 1998; Fenske et al. 1998). The results of the present
study show that, in both these GSD types, the mutated
gene is the one encoding the putative glucose-6-phos-
phate translocase, which we have now mapped to the
same region. All patients have mutations that result ei-
ther in (a) the substitution of highly conserved or semi-
conserved residues by amino acids with widely different
size or charge or (b) the truncation of the translocase,
with loss of the two lysine residues that are needed in
positions 3 and 4 (or 5) from the C-terminus to
retain proteins in the endoplasmic reticulum (Jackson et
al. 1990). These considerations indicate that the putative
glucose-6-phosphate translocase is most likely nonfunc-
tional in all patients reported here.
In 12 families of the 22 that were investigated here,
the patients were homozygous for some of the identified
mutations. This homozygosity was expected in some
cases, because of consanguinity (in the case of four fam-
ilies). It could be confirmed by analysis of the genomic
DNA of the parents in five of the other eight homozy-
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gous families. In 7 of the 10 combined-heterozygous
families, the availability of parental DNA enabled us to
show that the two mutations were on different chro-
mosomes.
Our finding that, in GSD types Ib and Ic, the same
mutations are present in the same gene could indicate
that glucose-6-phosphate and Pi (and PPi) are trans-
ported by the same protein. Accordingly, the bacterial
hexose 6-phosphate and glycerol 3-phosphate translo-
cases, to which the human putative glucose-6-phosphate
translocase is homologous (Gerin et al. 1997), act as
inorganic phosphate/phosphate ester exchangers (Ma-
loney et al. 1990). However, this argument, based on
homology, is not conclusive (Maloney and Wilson
1996), since the same superfamily of transporters com-
prises uniports (transporting only one substrate at a
time), symports (transporting two substrates in the same
direction), and antiports (transporting two substrates in
opposite directions; these are also known as “exchang-
ers”). Furthermore, Arion et al. (1980) concluded, on
the basis of kinetic studies performed on intact and de-
tergent-treated microsomes, that the glucose-6-phos-
phate and the Pi transporters were different. This is also
indicated by the discovery of a novel class of compounds,
derived from chlorogenic acid, that behave as specific
inhibitors of glucose-6-phosphate but not of PPi trans-
port (Arion et al. 1998a, 1998b) as well as by the dis-
tinctive behavior that the two transport functions have
in development (Goldsmith and Stetten 1979; Burchell
et al. 1990). One might argue, though, that two different
domains of the same protein could be involved in the
transport of glucose-6-phosphate and Pi (or PPi).
If there are indeed two separate transporters for Pi
and glucose-6-phosphate, then we have to admit that
measurement of the latencies of glucose-6-phosphatase
and pyrophosphatase does not allow us to differentiate
correctly the Pi and glucose-6-phosphate transport de-
fects. This would explain why patients with the same
mutations have been diagnosed as GSD types Ib and Ic.
The technical difficulties encountered in such assays
should not be underestimated, since the diagnosis is best
performed on homogenates prepared from fresh liver-
biopsy material (Narisawa et al. 1978; Lange et al. 1980;
Nordlie et al. 1983) and often has to be realized on small
liver samples obtained by needle biopsy. Interestingly,
Nordlie et al. (1983) concluded, in their original report
on GSD type Ic, that their patient must also have a defect
in the glucose-6-phosphate translocase. Their argument
was that they did not observe the time-dependent in-
hibition of glucose-6-phosphatase that they would have
expected to find if the decrease in glucose-6-phosphatase
activity had been due only to accumulation of inorganic
phosphate in the microsomes. Evidence for simultaneous
defects in the transport of inorganic phosphate and glu-
cose-6-phosphate was also reported for another case
(Hawkins et al. 1995), though one patient recently stud-
ied by Marcolongo et al. (1998), in whom Pi and glu-
cose-6-phosphate transport were measured by light scat-
tering, was reported to have an isolated Pi-transport
defect. Now that the gene encoding the putative glucose-
6-phosphate translocase has been identified, it will be
possible to determine whether all “non-a” forms of GSD
type I are due to mutations in this gene. Moreover, func-
tional studies should also enable to verify whether the
protein encoded by the gene on chromosome 11q23 is
a translocase acting independently of the hydrolase,
which would argue against the conformational models.
All the patients described in table 1 had some degree
of neutropenia, which is probably not due to functional
glucose-6-phosphatase deficiency, since there is usually
no neutropenia in GSD type Ia (Chen and Burchell
1995). Glucose-6-phosphate could be transported into
the endoplasmic reticulum to supply substrate to en-
zyme(s) other than the glucose-6-phosphate hydrolase.
One candidate is hexose-6-phosphate dehydrogenase, a
glucose-6-phosphate dehydrogenase isozyme that is
present in the microsomes in several tissues (Takahashi
and Hori 1978). Both the existence of this isozyme in
neutrophils and its role in their metabolism will need to
be investigated. In conclusion, the present study opens
the possibility of diagnosing, at the gene level, most if
not all cases of GSD type I that are not due to mutations
in the phosphohydrolase gene.
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